BEDFORD, Mass., June 12, 2023 (WORLD NEWSWIRE) — Lantheus Holdings, Inc. (the Company) (NASDAQ: LNTH), a business devoted to enhancing client results through diagnostics, radiotherapeutics and expert system services that make it possible for clinicians to Find, Fight and Follow illness, revealed it will provide the following discussions at the upcoming 2023 Society for Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting, which will be held June 24-27, 2023 in Chicago, Illinois.
PYLARIFY AI™ (aPROMISE) is the just deep knowing allowed FDA-cleared medical gadget software to use standardized PSMA family pet reporting with PYLARIFY AI on PSMA PET/CT images, consisting of those attained utilizing PYLARIFY® (piflufolastat F18) family pet/CT.1 Standardized PSMA PET reporting supplies constant and exact illness concern metrology in assistance of client management and tracking with time.2,3,4
“We’re thrilled to present compelling data on the real-world application of AI-enabled PSMA PET imaging at SNMMI,” said Etienne Montagut, Chief Business Officer, Lantheus. “The presentations by Dr. Angellica Gordon from UCLA and Dr. Hong Song from Stanford reflect a significant milestone in our relentless pursuit of advancing prostate cancer management through cutting-edge technology and innovation. By harnessing our deep learning algorithm and extensive datasets, we are committed to sustaining our efforts to improve guidance for prostate cancer patient diagnosis and treatment.”
Presentation information are as follows:
Date & Time: Sunday, June 25, 2023, 11:00 am – 12:30 pm CT
Session Title: Physics, Instrumentation & Data Sciences
Title: Use of aPROMISE as an expert system software to automate and standardize quantitative heterogeneity of PSMA and FDG PET/CT in clients with mCRPC prior to PSMA radioligand treatment: a proof-of-concept research study
Presenter: Angellica Gordon, MD, PGY-3 Nuclear Medicine Resident, UCLA
Poster Number: P228
Date & Time: Monday, June 26, 2023, 11:15 am – 12:45 pm CT
Session Title: Oncology: Clinical Therapy & Diagnosis (consists of Phase 2, Phase 3, post approval research studies)
Title: Total and Anatomically Contextualized Quantitative 18F-DCFPyL family pet at biochemical reoccurrence anticipates subsequent biochemical development complimentary survival in prostate cancer clients
Presenter: Hong Song, MD, Assistant Professor of Radiology (Nuclear Medicine), Stanford
Poster Number: P837
About Lantheus
With more than 65 years of experience in providing life-altering science, Lantheus is devoted to enhancing client results through diagnostics, radiotherapeutics and expert system services that make it possible for clinicians to Find, Fight and Follow illness. Lantheus is headquartered in Massachusetts and has workplaces in New Jersey, Canada and Sweden. For more info, go to www.lantheus.com.
Safe Harbor for Forward-Looking and Cautionary Statements
This news release consists of “forward-looking statements” within the significance of the Private Securities Litigation Reform Act of 1995, as changed, that undergo dangers and unpredictabilities and are made pursuant to the safe harbor arrangements of Section 27A of the Securities Act of 1933, as changed, and Section 21E of the Securities Exchange Act of 1934, as changed. Forward-looking declarations might be recognized by their usage of terms such as “can,” “introduce,” “potential” and other comparable terms. Such positive declarations are based upon present strategies, quotes and expectations that undergo dangers and unpredictabilities that might trigger real outcomes to materially vary from those explained in the positive declarations. The addition of positive declarations must not be considered a representation that such strategies, quotes and expectations will be attained. Readers are warned not to put unnecessary dependence on the positive declarations consisted of herein, which speak just since the date hereof. The Company carries out no responsibility to openly update any positive declaration, whether as an outcome of brand-new info, future advancements or otherwise, other than as might be needed by law. Risks and unpredictabilities that might trigger our real outcomes to materially vary from those explained in the positive declarations consist of (i) our capability to effectively launch PYLARIFY AI as a business item; (ii) the marketplace receptivity to PYLARIFY AI as a brand-new digital application for quantitative evaluation of PSMA PET/CT images in prostate cancer; (iii) the copyright security of PYLARIFY AI; (iv) disruptions or efficiency issues connected with our digital application, consisting of a service interruption; (v) a network or information security event that permits unapproved access to our network or information or our consumers’ information; and (vi) the dangers and unpredictabilities gone over in our filings with the Securities and Exchange Commission (consisting of those explained in the Risk Factors area in our Annual Reports on Form 10-K and our Quarterly Reports on Form 10-Q).
1https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm?ID=K211655
2https://pubmed.ncbi.nlm.nih.gov/34463809/
3https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm?ID=K220590
4https://jnm.snmjournals.org/content/63/supplement_2/2496
Contacts:
Mark Kinarney
Vice President, Investor Relations
978-671-8842
[email protected]
Melissa Downs
Senior Director, Corporate Communications
646-975-2533
[email protected]
